CoChat

Enhancing and stabilizing monoclonal antibody production by Chinese hamster ovary (CHO) cells with optimized perfusion culture strategies

Open access
Liang, Kexue, Luo, Hongzhen, Li, Qi · 2023 · Frontiers in Bioengineering and Biotechnology

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index; 3 of the 15 sources its claims cite were checked for support.

Abstract

The perfusion medium is critical in maintaining high cell concentration in cultures for the production of monoclonal antibody by Chinese hamster ovary cells. In this study, the effects of perfusion culture strategies when using different media on the process stability, product titer, and product quality were investigated in 3-L bioreactor. The results indicated that continuous perfusion could maintain higher levels of cell density, product titer, and quality in comparison with those of the intermittent perfusion culture. Next, the perfusion culture conditions with different perfusion rates and temperature reduction methods were further optimized. When combining the high perfusion rates and delayed reduction of culture temperature at day 6, the product titer reached a higher level of 16.19 g/L with the monomer relative abundant of 97.6%. In this case, the main peak of the product reached 56.3% and the total N-glycans ratio was 95.2%. To verify the effectiveness of the optimized perfusion culture in a larger scale, a 200-L bioreactor was used to perform and the final product titer reached the highest level of 16.79 g/L at day 16. Meanwhile, the product quality (monomer abundant of 97.6%, main peak of 56.3%, and N-glycans ratio of 96.5%) could also be well maintained. This study provided some guidance for the high-efficient production of monoclonal antibody by CHO cells via optimized perfusion culture strategy.

Overview

CoChat Summary

TL;DR

Continuous perfusion outperformed intermittent perfusion for CHO-cell anti-PD-1 mAb production, and an optimized high-perfusion-rate strategy with delayed temperature reduction increased titer and maintained product quality. The optimized strategy was verified in a 200-L bioreactor, reaching 16.79 g/L at day 16 with comparable quality to the 3-L process.

Key findings

  • Continuous perfusion maintained higher cell density, titer, and quality than intermittent perfusion: run #3 (intermittent) produced 4.39 g/L at day 14 versus 8.73–9.83 g/L in continuous runs #1–#4, and run #3 had the highest aggregate abundance at 3.5% versus 2.1%–2.2% in continuous runs #1–#2.
  • The optimized 3-L strategy (run #8: higher perfusion rates plus temperature reduction at day 6) reached 16.19 g/L at day 16, with monomer relative abundance 97.6%, main peak 56.3%, and total N-glycans 95.2%; mAb production rate was 1.572 g/L/day.
  • In the 200-L bioreactor (run #9), the final titer reached 16.79 g/L at day 16, comparable to run #8 (p > 0.05), with monomer 97.6%, main peak 56.3%, and total N-glycans 96.5%; pCO2 reached ∼175 mmHg after day 10, significantly higher than in the 3-L run #8 (p < 0.05).
  • BM-II, FM-III, and FM-IV could replace the commercial media used in run #1; run #2 had a main peak of 55.4%, higher than run #1 and run #4 (both 49.5%), while run #4 had acidic variants at 27.5% and run #1 had basic variants at 28.4%.

Methods

  • CHO cells producing anti-PD-1 mAb were cultured in 3-L bioreactors for runs #1–#8 and a 200-L bioreactor for run #9, using ATF with 50 kDa hollow fiber membranes; inoculation density was 1.5×10^6 cells/mL (2 L for 3-L runs, 180 L for the 200-L run).
  • Culture conditions included pH 6.80–6.90, agitation at 250 rpm, DO at 40 ± 15% air saturation, initial temperature 36.5°C, and temperature reduction to 31.0°C at day 5 or day 6; perfusion rates and media varied across runs, with continuous versus intermittent perfusion compared.
  • Analytics included daily VCD/viability, mAb titer by POROS A20 HPLC, SEC-HPLC for monomer/aggregate, CEX-HPLC for charge variants, HPLC-based N-glycan profiling, and glucose/lactate/osmolality/pCO2 measurements; data are mean ± SD of three biological independent experiments, with two-tailed Student’s t-test at p < 0.05.

Limitations

  • The paper states that the effectiveness of the optimized perfusion culture strategy for other mAbs and recombinant biopharmaceutical proteins will be further investigated for process intensification.
  • Evident from the design: the study tests only one anti-PD-1 mAb/CHO cell line and does not include a fed-batch comparator, so broader generalizability to other products or process modes is not established.
  • Evident from the results: the 200-L run showed lower peak VCD than the 3-L run #8 (73.0×10^6 vs. 80.5×10^6 cells/mL) and higher pCO2 (∼175 mmHg after day 10), indicating scale-related differences that may affect process performance.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fbioe.2023.1112349

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

FIGURE 1 Schematic diagram of the CHO perfusion culture for the production of anti-PD-1 monoclonal antibody (mAb).
FIGURE 1 Schematic diagram of the CHO perfusion culture for the production of anti-PD-1 monoclonal antibody (mAb).CC BY · PubMed Central
FIGURE 2 Changing profiles of viable cell density (VCD) (A), viability (B), glucose concentration (C), lactate concentration (D), osmolality (Osmo) (E), and pCO2 (F) during perfusion cultures using different media in 3-L bioreactor. The error bars indicate the standard deviations (SD) of three independent experiments. Continuous perfusion: run #1, #2, and #4; intermittent perfusion: run #3. The perfusion rates and conditions in the four runs were shown in Table 1.
FIGURE 2 Changing profiles of viable cell density (VCD) (A), viability (B), glucose concentration (C), lactate concentration (D), osmolality (Osmo) (E), and pCO2 (F) during perfusion cultures using different media in 3-L bioreactor. The error bars indicate the standard deviations (SD) of three independent experiments. Continuous perfusion: run #1, #2, and #4; intermittent perfusion: run #3. The perfusion rates and conditions in the four runs were shown in Table 1.CC BY · PubMed Central
FIGURE 3 Profiles of mAb titer (A), monomer and aggregate relative abundance (B), variant contents (C), and percentages of N-glycans (D) under perfusion cultures of run #1-#4. The error bars indicate the SD of three independent experiments.
FIGURE 3 Profiles of mAb titer (A), monomer and aggregate relative abundance (B), variant contents (C), and percentages of N-glycans (D) under perfusion cultures of run #1-#4. The error bars indicate the SD of three independent experiments.CC BY · PubMed Central
FIGURE 4 Changing profiles of VCD (A), viability (B), glucose concentration (C), lactate concentration (D), Osmo (E), and pCO2 (F) during different perfusion cultures in 3-L bioreactor. The error bars indicate the SD of three independent experiments.
FIGURE 4 Changing profiles of VCD (A), viability (B), glucose concentration (C), lactate concentration (D), Osmo (E), and pCO2 (F) during different perfusion cultures in 3-L bioreactor. The error bars indicate the SD of three independent experiments.CC BY · PubMed Central
FIGURE 5 Profiles of mAb titer (A), monomer and aggregate relative abundance (B), variant contents (C), and percentages of N-glycans (D) during perfusion cultures of run #5-#8. The error bars indicate the SD of three independent experiments.
FIGURE 5 Profiles of mAb titer (A), monomer and aggregate relative abundance (B), variant contents (C), and percentages of N-glycans (D) during perfusion cultures of run #5-#8. The error bars indicate the SD of three independent experiments.CC BY · PubMed Central
FIGURE 6 Changing profiles of VCD and viability (A), glucose and lactate concentration (B), Osmo and pCO2 (C), and titer (D) during the optimized perfusion culture in a 200-L bioreactor. The error bars indicate the SD of three independent experiments.
FIGURE 6 Changing profiles of VCD and viability (A), glucose and lactate concentration (B), Osmo and pCO2 (C), and titer (D) during the optimized perfusion culture in a 200-L bioreactor. The error bars indicate the SD of three independent experiments.CC BY · PubMed Central

Verification

Claims the paper makes

3 Valid · 0 Not valid · 9 Not checked · 88 Own results and interpretations

66 more claims

Create a free account to see all 100 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 21
  • Probably not a substantial claim. 7
  • The quote only partly states this claim. 4

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 38 references

Cited by

See all 37

Metadata

Authors
Liang, K., Luo, H., & Li, Q.
Affiliations
Jiangnan University (CN)
Corresponding author
Li, Qi
Venue
Frontiers in Bioengineering and Biotechnology
Published
2023-01-20
Volume
11
Pages
1112349-1112349
ISSN
2296-4185 (ISSN-L)
OpenAlex
W4317521338
Cited by
37
References
38
Citations by year
2026: 18 · 2025: 9 · 2024: 8 · 2023: 2
FWCI
2.86
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Bioengineering and Biotechnology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Keywords
monoclonal antibody production, CHO cells, perfusion culture, continuous perfusion, perfusion rate, product titer, bioreactor scale-up, process stability

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Enhancing and stabilizing monoclonal antibody production by Chinese hamster ovary (CHO) cells with optimized perfusion culture strategies. https://app.cochat.ai/papers/10.3389/fbioe.2023.1112349
The paper
Liang, K., Luo, H., & Li, Q. (2023). Enhancing and stabilizing monoclonal antibody production by Chinese hamster ovary (CHO) cells with optimized perfusion culture strategies. Frontiers in Bioengineering and Biotechnology. https://doi.org/10.3389/fbioe.2023.1112349

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.